MINIPRES

This brand name is authorized in Estonia, Malta, Mexico

Active ingredients

The drug MINIPRES contains one active pharmaceutical ingredient (API):

1 Prazosin
UNII XM03YJ541D - PRAZOSIN

Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease.

Read about Prazosin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C02CA01 Prazosin C Cardiovascular system → C02 Antihypertensives → C02C Antiadrenergic agents, peripherally acting → C02CA Alpha-adrenoreceptor antagonists
Discover more medicines within C02CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1665020, 1665985, 1822216
Country: MT Medicines Authority Identifier(s): AA565/79301
Country: MX Comisiรณn Federal para la Protecciรณn contra Riesgos Sanitarios Identifier(s): 79195

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.